CAJ | 학술논문

目的：探讨归芪三七口服液联合恩替卡韦(ETV)在HBV相关性肝癌经动脉栓塞化疗(TACE)中的临床应用价值。方法：将80例患者随机分为对照组与治疗组各40例，2组均在行TACE治疗前始给予恩替卡韦治疗，治疗组在恩替卡韦治疗的同时加用归芪三七口服液治疗，行TACE治疗后1月监测血常规、肝脏功能、HBV DNA定量的变化情况。结果：治疗组血常规、肝脏功能的改善情况明显优于对照组（P＜0.05），但HBV DNA定量2组无明显差异(P＞0.05)。结论：归芪三七口服液联合恩替卡韦在HBV相关性肝癌行TACE治疗后，可以降低肝脏损害的严重程度，预防肝功能的进一步恶化。
목적：탐토귀기삼칠구복액연합은체잡위(ETV)재HBV상관성간암경동맥전새화료(TACE)중적림상응용개치。방법：장80례환자수궤분위대조조여치료조각40례，2조균재행TACE치료전시급여은체잡위치료，치료조재은체잡위치료적동시가용귀기삼칠구복액치료，행TACE치료후1월감측혈상규、간장공능、HBV DNA정량적변화정황。결과：치료조혈상규、간장공능적개선정황명현우우대조조（P＜0.05），단HBV DNA정량2조무명현차이(P＞0.05)。결론：귀기삼칠구복액연합은체잡위재HBV상관성간암행TACE치료후，가이강저간장손해적엄중정도，예방간공능적진일보악화。
Objective:To explore clinical application value of GuiQi SanQi oral liquid and entecavir tablets to transcatheter arterial chemoembolization (TACE) in treating HBV related hepatocellular carcinoma. Method:All 80 patients were randomized into the control group and the treatment group. Both groups took entecavir tablets before TACE was performed, and the treatment group were also given with GuiQi SanQi oral liquid, routine blood test, liv-er function and quantitative HBV DNA were monitored after TACE was performed in one month. Result:The im-provements of routine blood test and liver function in the treatment group were superior to these of the control group (P<0.05), but the comparison between both groups had insignificant difference in quantitative HBV DNA. Conclu-sion:GuiQi SanQi oral liquid and entecavir could reduce the severity of liver damage and prevent further deteriora-tion of liver function in treating HBV related hepato cellular carcinoma.